Liking Amphetamine Linked to Reduced Risk of Mental Disorders

Discover how euphoric responses to amphetamine are linked to gene variants offering protection against ADHD and schizophrenia, revealing surprising insights into mental disorder risks.

Written byEmily Willingham
Published Updated 4 min read
Amphetamines.
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Ritalin, 20 mgU.S DRUG ENFORCEMENT AGENCYA euphoric response to amphetamine could signal the presence of gene variants associated with protection against attention deficit-hyperactivity disorder (ADHD) and schizophrenia. Published in PNAS, a team led by Abraham Palmer reported having found that DNA differences associated with amphetamine response are also correlated with a reduced risk for both conditions.

The results link two disorders that are treated in opposing ways: people with schizophrenia are often given drugs to block dopamine signaling, while those with ADHD are typically given drugs that imitate dopamine. So identifying a common feature between them is “interesting and somewhat surprising,” Philip Asherson, a molecular psychiatrist at King’s College London, told The Scientist. Asherson, who was not involved in the study, called the results convincing: “to have these findings by chance does seem unlikely,” he said.

“I might’ve predicted that whichever way it went for schizophrenia, it would go the opposite way for ADHD because of what we use to treat these disorders,” said Palmer. “But in fact, that’s not what we saw. So that’s a little bit surprising.”

Palmer’s team ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies